# TELA Bio Forecasts 3.4% Revenue Decline to $19.995 Million Ahead of November 10 Results

> TELA Bio is expected to report a 3.4% revenue decline to $19.995 million and a 16-cent loss per share when it releases quarterly results on November 10.

- Published: 2026-11-07T00:56:59+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-07/tela-bio-revenue-decline-earnings-preview
- Source: [The future of trading](https://capital.com/en-int/news/tela-bio-inc-tela-oq-expected-to-post-a-loss-of-16-cents)

## Key takeaways

- TELA Bio is expected to report a 3.4% revenue decrease to $19.995 million for the quarter ending September 30, 2026.
- The mean analyst estimate from five analysts points to a loss of 16 cents per share.
- TELA Bio's median 12-month price target is $2.00, about 143.9% above its last closing price of $0.82.

TELA Bio Inc is expected to report a 3.4% revenue decline to $19.995 million for the quarter ending September 30, 2026, and a loss of 16 cents per share, according to [The future of trading](https://capital.com/en-int/news/tela-bio-inc-tela-oq-expected-to-post-a-loss-of-16-cents). The Malvern, Pennsylvania-based medical technology company is scheduled to release results on November 10.

## TELA Bio's Quarterly Estimates and Analyst Ratings

The revenue estimate comes from the mean of five analysts, based on LSEG data, and compares with $20.69 million a year earlier. LSEG's mean analyst estimate for TELA Bio is a loss of 16 cents per share. The mean earnings estimate was unchanged over the last three months.

The current average analyst rating on the shares is "buy," with four "strong buy" or "buy" recommendations, one "hold" and no "sell" or "strong sell." Wall Street's median 12-month price target is $2.00, about 143.9% above the last closing price of $0.82.

TELA Bio has missed the LSEG earnings estimate in its two most recent quarters. For the quarter ending June 30, 2026, the estimate was a loss of 18 cents per share and the actual result was a loss of 20 cents, a miss of 12.2%. For the quarter ending March 31, 2026, the estimate was a loss of 19 cents and the actual result was a loss of 21 cents, a miss of 11.6%. In the quarter ending December 31, 2025, TELA Bio beat the estimate of a loss of 18 cents with an actual loss of 17 cents, a beat of 6.9%.

## TELA Bio's Cost Cuts and Leadership Changes

TELA Bio's CFO stepped down as the company cut 20% of its workforce and $17 million in annual costs, AInvest reported on August 31, 2026. Revenue fell 4% to $19.3 million in the second quarter of 2026, with a net loss of $11.3 million and $30.4 million in cash, according to the same report.

On August 4, 2026, TELA Bio named Heather Getz as CEO and director, succeeding founder and former CEO Antony Koblish, Seeking Alpha reported. On October 8, 2026, TELA Bio held a virtual special meeting to approve a reverse stock split if needed to raise the per-share trading price, and the company stated it was currently in compliance and had no need to execute the split at that time, Seeking Alpha reported.

## TELA Bio's November 10 Results Release

TELA Bio is scheduled to report results on November 10 for the period ending September 30, 2026, according to The future of trading. The report will show whether the company's revenue and per-share loss land at the analyst estimates described above.

## Companies in this story

- TELA Bio · website: http://telabio.com

---
News for Agent · https://newsforagent.com/llms.txt